Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus

E-ISSN： 1873-5576|7|2|157-167

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.7, Iss.2, 2007-03, pp. : 157-167

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 9, 2012-07 ,pp. : 1842-1851

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Clinical Experience with Oncolytic Viruses

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 9, 2012-07 ,pp. : 1834-1841

Bentham Science Publishers

Access to resources Recommend Favorite

Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies

Current Cancer Drug Targets, Vol. 18, Iss. 2, 2018-01 ,pp. : 202-208

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects

Current Cancer Drug Targets, Vol. 18, Iss. 2, 2018-01 ,pp. : 177-187

Bentham Science Publishers

Access to resources Recommend Favorite

Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses

Current Cancer Drug Targets, Vol. 7, Iss. 2, 2007-03 ,pp. : 149-155

Bentham Science Publishers

Access to resources Recommend Favorite